Please assess the completion status of the following clinical trial:

Trial Title: S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or pathologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer~  * No mixed mullerian and borderline ovarian tumors~* Surgically staged as stage III or IV at initial diagnosis~* Must meet one of the following criteria for refractory/relapsed disease:~  * Relapsed within 6 months after completing front-line concurrent or sequential platinum (either cisplatin or carboplatin) and taxane (paclitaxel or docetaxel) chemotherapy~ * Had a best response of increasing disease during this front-line regimen~    * Consolidation chemotherapy and reinduction therapy are counted as part of the front-line regimen~* Unidimensionally measurable disease~  * At least 2 cm by medical photograph (skin or oral lesion), palpation, plain x-ray, CT scan, MRI, or other conventional technique (bone lesions not included)~ * At least 1 cm by spiral CT scan~ * Measurable disease must remain outside of radiotherapy field~* If the tumor is known to be KIT (CD117) or PDGFR positive, patient must be offered SWOG-S0211 if available~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Cardiovascular~* No myocardial infarction within the past 6 months~* No angina pectoris~* No uncontrolled congestive heart failure~* No uncontrolled cardiac arrhythmia~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except for the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Carcinoma in situ of the cervix~ * Adequately treated stage I or II cancer from which the patient is currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No more than 1 prior biological response modifier~* At least 28 days since prior biological response modifier and recovered~Chemotherapy~* See Disease Characteristics~* No prior topotecan or other topoisomerase I inhibitor~* One other additional prior chemotherapy regimen allowed~* At least 28 days since prior chemotherapy (14 days for weekly chemotherapy) and recovered~Endocrine therapy~* Prior hormonal therapy allowed~* No concurrent hormonal therapy~Radiotherapy~* At least 28 days since prior radiotherapy and recovered~* No prior radiotherapy to more than 25% of bone marrow~* No concurrent palliative radiotherapy~Surgery~* At least 14 days since prior major surgery and recovered~Other~* At least 28 days since prior investigational drugs and recovered~* No other concurrent antitumor therapy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- irinotecan (Type: EXPERIMENTAL): irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues